Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Article  PubMed  CAS  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655–68.

Article  PubMed  CAS  Google Scholar 

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181–95.

Article  PubMed  CAS  Google Scholar 

Moehler MH, Kato K, Arkenau HT, Oh DY, Tabernero J, Cruz-Correa M, et al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J Clin Oncol. 2023;41:286.

Article  Google Scholar 

Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330:2064–74.

Article  PubMed  PubMed Central  Google Scholar 

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449–58.

Article  PubMed  CAS  Google Scholar 

van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev. 2020;86: 102024.

Article  PubMed  Google Scholar 

Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019;24:103–9.

Article  PubMed  CAS  Google Scholar 

Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, et al. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40:392–402.

Article  PubMed  CAS  Google Scholar 

Lei M, Janjigian YY, Ajani JA, Moehler M, Wang X, Shen L, et al. Abstract CT023: Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses. Cancer Research. 2022;82:CT023.

Article  Google Scholar 

Park YG, Kim HD, Hyung J, Park YS, Ryu MH. Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair. Gastric Cancer. 2024;27:840–9.

Article  PubMed  CAS  Google Scholar 

Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137:824–33.

Article  PubMed  Google Scholar 

Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H. Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes. Lab Invest. 1996;75:67–76.

PubMed  CAS  Google Scholar 

Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18:473–87.

Article  PubMed  Google Scholar 

Lima Á, Sousa H, Medeiros R, Nobre A, Machado M. PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis. Discov Oncol. 2022;13:19.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xie T, Liu Y, Zhang Z, Zhang X, Gong J, Qi C, et al. Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study. J Immunother. 2020;43:139–44.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim JH, Ryu MH, Park YS, Ma J, Lee SY, Kim D, et al. Predictive biomarkers for the efficacy of nivolumab as ≥ 3(rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. BMC Cancer. 2022;22:378.

Article  PubMed  PubMed Central  Google Scholar 

Lee CK, Lee JB, Park SJ, Che J, Kwon WS, Kim HS, et al. Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study. Gastric Cancer. 2024;27:118–30.

Article  PubMed  CAS  Google Scholar 

Kim HD, Shin J, Song IH, Hyung J, Lee H, Ryu MH, et al. Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy. Gastric Cancer. 2024;27:819–26.

Article  PubMed  CAS  Google Scholar 

Kim HD, Shin J, Hyung J, Lee H, Moon M, Ma J, et al. Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression. Gastric Cancer. 2025;28:74–82.

Article  PubMed  CAS  Google Scholar 

Kim EJ, Chae H, Park YS, Ryu MH, Kim HD, Shin J, et al. Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy. Gastric Cancer. 2024;27:146–54.

Article  PubMed  CAS  Google Scholar 

Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology. 2016;6:227.

PubMed  Google Scholar 

Van Steen K, Curran D, Kramer J, Molenberghs G, Van Vreckem A, Bottomley A, et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med. 2002;21:3865–84.

Article  PubMed  Google Scholar 

Choi E, Shin J, Ryu M-H, Kim H-D, Park YS. Heterogeneity of claudin 182 expression in metastatic gastric cancer. Scientif Rep. 2024;14:17648.

Article  CAS  Google Scholar 

Kim HD, Choi E, Shin J, Lee IS, Ko CS, Ryu MH, et al. Clinicopathologic features and prognostic value of claudin 182 overexpression in patients with resectable gastric cancer. Sci Rep. 2023;13:20047.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Stanland LJ, Luftig MA. The role of EBV-induced hypermethylation in gastric cancer tumorigenesis. Viruses. 2020;12:1222.

Article  PubMed  PubMed Central  CAS  Google Scholar